ARS Pharmaceuticals (SPRY) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for EURneffy for the emergency treatment of allergic reactions in adults and children who weigh greater than 30 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY: